Table 1.
Characteristics of adverse events of prostate cancer treatments in the United States.
Fig 1.
Data are from US FDA’s Adverse Event Reporting System (FAERS) through to April 30, 2024. Group 1, Enzalutamide with other medications (excluding other ARPIs); Group 2, Apalutamide with other medications (excluding other ARPIs); Group 3, Darolutamide with other medications (excluding other ARPIs); Group 4, Abiraterone with other medications (excluding other ARPIs); Group 5, Abiraterone + Enzalutamide with other medications (excluding Apalutamide or Darolutamide). P-value, Chi-square test or Fisher’s exact test. Missing values removed.
Table 2.
Adverse Events of prostate cancer treatments in the United States by age group.
Table 3.
Adverse Events of prostate cancer treatments in the United States by treatment group.
Fig 2.
Proportional reporting ratios and 95% confidential intervals in Group 1 to Group 5.
Data are from US FDA’s Adverse Event Reporting System (FAERS) through to April 30, 2024. Group 1, Enzalutamide with other medications (excluding other ARPIs); Group 2, Apalutamide with other medications (excluding other ARPIs); Group 3, Darolutamide with other medications (excluding other ARPIs); Group 4, Abiraterone with other medications (excluding other ARPIs); Group 5, Abiraterone + Enzalutamide with other medications (excluding Apalutamide or Darolutamide). PRR, proportional reporting ratio. Top 3 statistically high risk adverse events by group.